展览5.1
客户：23553-00003
2024年10月1日
Dianthus Therapeutics, Inc.
7 帝国广场，43号rd
纽约市，纽约州10036 电话：+1 646 397 3970
| 关于： | Dianthus Therapeutics, Inc. |
号码：333-280982 S-3
女士们先生们：
我们已成为Dianthus Therapeutics, Inc.的律师，一家特拉华州的公司（“公司），现专门与证券交易委员会（以下简称“交易委员会”）准备和提交一份S-3表格的注册声明（以下简称“注册声明”）。委员会:表格号：333-280982 S-3 (“本登记声明”) 由特立软件股份有限公司，一家德拉华州股份公司 (以下简称为“本公司”) 提交，目的是为了注册其额外的7,184,563股A类普通股，每股面值$0.0001 (以下简称为“A类普通股”), 以及在特立软件股份有限公司 2022年股权激励计划下可发行股份的1,436,911股A类普通股，注(下文简称为“A类普通股”)。苹果公司CEO库克大规模抛售股票，套现逾3亿港元，资金已存入上市公司设立的专项账户(“信托账户”)，以公共股东(定义详见下文)为受益人的注册声明(FORM S-1)中所规定的一定金额及特定款项。信托账户中持有的基金类型(包括资金持有的利息)除支付公司税费以外，一旦实现以下最早的情况之一即可支取: (i) 完成首次（业务）组合；(ii) 如果公司未能在2025年3月3日之前完成首次（业务）组合，则可以赎回100%的发行股份（如下所述）；或 (iii) 股东表决赎回发行股份。 若要批准修订本Amended and Restated Certificate，必须就修订对决定最早如下情形之一的公司的义务以在首次业务组合中允许赎回或未在终止日期之前完成首次业务组合即赎回100%的发行股份产生影响或涉及股东权益或首次业务组合前的活动（如第9.7节所述），对修订进行表决。发售期(“发售期”)所出售单位的组成部分的Common Stock股份的持有人(“发售股份”)，不论这些发售股份是在发售期内还是在发售市场上的二级市场中购买，也不论这些持有人是公司的发起人，高管或董事，或上述任何关联方的子公司，均在此被称为“公共股东”。证券法第1933号修正案（以下称“证券法”）证券法”), 与《证券法》下的注册有关，并根据《证券法》第415条规定，随时发行和销售，可以一起或分开，可以分为一个或多个系列（如适用）：
（i）公司的债务证券（“债务证券。”);
(ii) 公司普通股每股面值为$0.001的股份（"普通股”);
(iii) 公司优先股每股面值为$0.001的股份（"优先股”);
(iv) 用于购买债务证券、普通股或优先股的认股证（"权证”）;并
(v) 公司单位包括任何债务证券、普通股、优先股或认股权（"单位”).
债务证券、普通股、优先股、认股权证和单位在本文中统称为“证券。”债务证券将根据注册声明附表所附的实质相同的契约发行（“基础信托协议”).
在下文表达的意见时，我们已经审查了原件或已由我们确认为真实和完整副本的副本，形式为基础信托和其他文件、公司记录、公司及公共官员的官员认证书、以及我们认为有必要或建议的其他工具，以便我们能够发表这些意见。在我们的审查中，我们假设所有签名的真实性，所有自然人的法定资格和能力，提交给我们的所有文件的真实性，以及提交给我们的所有文件作为副本的与原始文件一致性。关于这些意见所涉及的任何重要事实，我们已经根据我们认为适当的程度依赖于公司及其他代表人员提供的声明和陈述，而无需进行独立调查。
吉布森德恩律师事务所 200 Park Avenue | New York, NY 10166-0193 | T: 212.351.4000 | F: 212.351.4035 | gibsondunn.com
San Francisco，加利福尼亚州94111-3715，艾梅巴卡德罗中心2600套房| 电话：415.393.8200 | 传真：415.393.8306 | gibsondunn.com
Dianthus Therapeutics, Inc.
2024年10月1日
第2页
我们在没有独立调查的情况下假设：
(i) 在根据注册声明销售任何证券的时候（“销售时点”），注册声明和其任何补充和修订文件（包括事后生效修正文件）将生效并符合所有适用法律；相关时点”，注册声明及其任何补充和修订（包括事后生效的修正）将生效并符合所有适用法律；
(ii)在相关时间，将准备一份简介说明书并提交给委员会，用于描述通过其募集的所有与证券相关的文件而且该简介说明书将符合所有適用法律;
（iii）所有证券将按照注册声明和适用的招股说明书中所述的方式发行和出售；
（iv）在相关时间，公司必须采取的所有法人或其他行动，以便合法授权每一次拟发行的证券和任何相关文件（包括（i）为行使、转换或交换任何证券以换取普通股或优先股而储备普通股或优先股的情况（“可转换安防-半导体），以及（ii）在有实物证券的情况下执行、交付和履行所需的证券及任何相关文件，这些文件在以下1至5段所述）已经得以完成，并仍然有效；
（v）发行任何普通股或优先股时，包括行使、转换或交换任何可转换证券时，发行和流通的普通股或优先股总数将不超过公司当时根据其公司章程及其他相关文件授权发行的普通股或优先股总数；
（vi）就债务证券而言，在相关时间，相关受托人应当依照1939年修订的《信托契约法》（“信托工业法(TIA)”）获得资格，受托人的资格声明应以表格 T-1 应已向委员会递交并关联基础契约应已由公司以及其他各方予以正式执行和交付，并在投资者关系协会下得到合法资格；
（七）在相关时间，有关任何已发行或发行的债券的决定性购买、承销或类似协议以及与之相关的任何其他必要协议将已经获得公司的所有必要董事会或其他行动的授权并由公司和其他相关方予以正式执行和交付。
Dianthus Therapeutics, Inc.
2024年10月1日
第3页
根据上述内容并依赖于该内容，以及在此规定的假设、例外、限制和限定条件下，我们认为：
| 1. | 关于任何债务证券，当： |
| a. | 该债务证券的条款和条件已根据相关基础信托文件的条款和条件通过补充信托契约或公司证书正式制定， |
| b. | 任何此类补充信托契约已由公司和相关受托人正式执行和交付（连同相关基础信托文件，称为“契约 |
| c. | 在适用的信托文件的条款下，这些债务证券已经执行（对于有证券的债务证券），交付和经过验证，并根据适用的确切购买，承销或类似协议颁发并出售。 |
这些债务证券将是公司的合法，有效和具有约束力的义务，并且按照各自的条款对公司执行。
| 2. | 关于任何优先股的股份： |
| a. | 涉及这些优先股的特许证书已经得到妥善执行，并已向特拉华州州务卿办公室进行了备案。 |
| b. | 这些股票已经发行，（i）根据适用的确切购买，承销或类似协议，并按照其中规定的有关代价颁发，或（ii）在行使，转换或交换任何可转换证券时，并且按照规定在此类可转换证券或管理此类可转换证券的工具中提供此类转换或行使的额外代价，该代价（包括支付的任何用于此类可转换证券的代价）不会少于优先股的面值。 每股 基础上，在任何情况下，此类基础不低于优先股的面值。 |
| c. | 任何此类可转换证券均已有效发行并已完全支付 可免评估 （对于股票证券）或者公司的合法、有效和具有约束力的义务，根据其条款对公司可执行 |
此类优先股股份将会有效发行，并已完全支付 无需追加认缴款。
Dianthus Therapeutics, Inc.
October 1, 2024
Page 4
| 3. | With respect to shares of Common Stock, when: |
| a. | such shares of Common Stock have been duly executed (in the case of certificated shares) and delivered either (i) in accordance with the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein, or (ii) upon conversion or exercise of any Convertible Security, in accordance with the terms of such Convertible Security or the instrument governing such Convertible Security providing for such conversion or exercise, and for any additional consideration specified therein, which consideration (including any consideration paid for such Convertible Security), on a per-share basis, shall in either event not be less than the par value of the Common Stock, and |
| b. | any such Convertible Security was previously validly issued and is fully paid and non-assessable (in the case of an equity Security) or is a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, |
such shares of Common Stock will be validly issued, fully paid and non-assessable.
| 4. | With respect to any Warrants, when: |
| a. | the warrant agreement relating to such Warrants (the “Warrant Agreement”), if any, has been duly executed and delivered by the Company and each other party thereto, |
| b. | the terms of the Warrants have been established in accordance with the Warrant Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement, and |
| c. | the Warrants have been duly executed (in the case of certificated Warrants) and delivered in accordance with the Warrant Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein, |
such Warrants will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.
| 5. | With respect to any Units, when: |
| a. | the unit agreement relating to the Units (the “Unit Agreement”), if any, has been duly executed and delivered by the Company and each other party thereto, |
| b. | the terms of the Units have been duly established in accordance with the Unit Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement, and |
| c. | the Units have been duly executed (in the case of certificated Units) and delivered in accordance with the Unit Agreement, if any, and the applicable definitive purchase, underwriting or similar agreement for the consideration provided for therein, |
the Units will be legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms.
Dianthus Therapeutics, Inc.
October 1, 2024
Page 5
The opinions expressed above are subject to the following exceptions, qualifications, limitations and assumptions:
A. We render no opinion herein as to matters involving the laws of any jurisdiction other than the State of New York and the United States of America and, for purposes of paragraphs 2 and 3 above, the Delaware General Corporation Law. We are not admitted to practice in the State of Delaware; however, we are generally familiar with the Delaware General Corporation Law as currently in effect and have made such inquiries as we consider necessary to render the opinions contained in paragraphs 2 and 3 above. This opinion is limited to the effect of the current state of the laws of the State of New York and the United States of America and, to the limited extent set forth above, the laws of the State of Delaware and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such laws or the interpretations thereof or such facts.
B. The opinions above with respect to the Indenture, the Debt Securities, the Warrants, the Warrant Agreement, the Units and the Unit Agreement (collectively, the “Documents”) are each subject to (i) the effect of any bankruptcy, insolvency, reorganization, moratorium, arrangement or similar laws affecting the rights and remedies of creditors’ generally, including without limitation the effect of statutory or other laws regarding fraudulent transfers or preferential transfers, and (ii) general principles of equity, including without limitation concepts of materiality, reasonableness, good faith and fair dealing and the possible unavailability of specific performance, injunctive relief or other equitable remedies regardless of whether enforceability is considered in a proceeding in equity or at law.
C. We express no opinion regarding the effectiveness of (i) any waiver of stay, extension or usury laws; (ii) provisions relating to indemnification, exculpation or contribution, to the extent such provisions may be held unenforceable as contrary to public policy or federal or state securities laws or due to the negligence or willful misconduct of the indemnified party; (iii) any provision in any Document waiving the right to object to venue in any court; (iv) any agreement to submit to the jurisdiction of any Federal court; (v) any waiver of the right to jury trial; or (vi) any provision to the effect that every right or remedy is cumulative and may be exercised in addition to any other right or remedy or that the election of some particular remedy does not preclude recourse to one or more others.
Dianthus Therapeutics, Inc.
October 1, 2024
Page 6
D. To the extent relevant to our opinions in paragraphs 4 and 5 and not covered by our opinions in paragraphs 1, 2 or 3, we have assumed that any securities underlying, comprising or issuable upon exchange, conversion or exercise of any Warrants or Units are validly issued, fully paid and non-assessable (in the case of an equity security) or a legal, valid and binding obligation of the issuer thereof, enforceable against such issuer in accordance with its terms.
You have informed us that you intend to issue Securities from time to time on a delayed or continuous basis, and we understand that prior to issuing any Securities pursuant to the Registration Statement (i) you will advise us in writing of the terms thereof, and (ii) you will afford us an opportunity to (x) review the operative documents pursuant to which such Securities are to be issued or sold (including the applicable offering documents), and (y) file such supplement or amendment to this opinion (if any) as we may reasonably consider necessary or appropriate.
We consent to the filing of this opinion as an exhibit to the Registration Statement, and we further consent to the use of our name under the caption “Legal Matters” in the Registration Statement and the prospectus that forms a part thereof. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.
| Very truly yours, |
| /s/ Gibson, Dunn & Crutcher LLP |